Dr. Zubair Malik Weighs in on the FDA’s Reintroduction of IBS-C Medication

Zubair Malik, MD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Director of the Esophageal Program at Temple University Hospital, offered his thoughts to Healio Gastroenterology about the U.S. Food and Drug Administration’s reintroduction of tegaserod (Zelnorm), a twice-daily oral treatment for irritable bowel syndrome with constipation, for women younger than 65.